HBV/HCV - Chronic Viral Hepatitis
The Silent Killer" - a serious
disorder caused by HBV and HCV that has a general tendency to progress to hepatic cirrhosis
and possibly even primary liver cancer.
BioMonde's response!
The Global Burden of viral hepatitis HBV and HCV
The commonest chronic viral infections are associated with Hepatitis B (HBV) with
170 million people and Hepatitis C (HCV) with up to 300 chronically
infected worldwide. Between 8,000 and 10,000 people die of hepatitis
C and 5,000 people die of hepatitis B annually in the US.
Problems associated with anti-viral treatments for HBV and HCV
- Chronic active hepatitis;
- Non-response;
- High occurrence of relapse;
- Adverse side-effects;
- Badly tolerated;
- Limited beneficial effects;
- Not readily available;
- Expensive;
- Broad exclusion criteria;
- Inconvenient delivery methods.

FDA-approved (HBV) Treatments
-
Baraclude (entecavir)
EpivirHBV (lamivudine; 3TC)
Intron A (interferon alfa-2b)
Hepsera (adefovir dipivoxil)
Pegasys (peginterferon alfa-2a)
Tyzeka (telbivudine)
FDA-approved (HCV) Monotherapies
-
Intron A
Roferon
Infergen
Pegasys
PEG-Intron
FDA-approved (HCV) Combination Therapies
-
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
-
Development of a optimized, safe, effective and affordable class
of novel anti-hepatoinflammatory (anti-hepatitis) and hepatoprotector umbelliferone
derivatives (4-meythylumbellierone).

- a adjunct to anti-viral treatment;
- a therapy for non-responders to anti-viral (interferon) treatment;
- a therapy for HBV and HCV induced Acute and Chronic Viral
Hepatitis;
- a therapy for any co-hosted combination of: HBV, HCV, HIV,
Cirrhosis, and Liver Cancer;
- a prophylaxis therapy for HBV and HCV antiviral treatment to maximize the efficacy and minimize
the adverse side
effects of interferon and other antiviral drugs;
- a therapy to manage Liver Cirrhosis;
- a therapy where anti-viral treatment was declined due to
exclusion criteria such as diabetic, drug, alcohol and other
problems.
Whilst anti-viral treatment targets the virus that causes Chronic
Viral Hepatitis, BioMonde focuses on managing Chronic Viral
Hepatitis.
Umbelliferone derivatives (4-meythylumbellierone) can greatly
lessen liver inflammation, Hepatitis, and dramatically improve
elevated liver enzymes, which are indications of Liver damage
associated with Chronic Viral Hepatitis, HBV and HCV. By controlling
liver inflammation and liver enzymes, it is possible to prevent and
minimize liver scarring (fibrosis), and progression to cirrhosis and
liver cancer, irrespective of viral loads.
Umbelliferone derivatives (4-meythylumbellierone) also stimulate
liver function, including the regeneration tissue damage. Whilst is
may not be possible to repair liver scarring (fibrosis) associated
with cirrhosis, it is possible to slow its progression.
BioMonde derivatives are not only an
ideal prophylaxis and adjunct to anti-viral treatment such as
Interferon, they offer a viable and
effective option for Interferon non-responders and many previously
excluded from anti-viral treatment. Consequently, BioMonde's
approach means that more HBV and HCV patients can have access to
effective healthcare.
REFERENCE MATERIAL
Published, Peer Reviewed Studies and Medical Opinion
click-here
View our product pipeline
click-here
Products containing umbelliferone derivatives
(4-Methylumbelliferone) click-here
HEPARVIT™
ProHEP
HBV Virus
HCV Virus


Medical research...........
Indicates that umbelliferone derivatives (4-meythylumbellierone)
administered with or without anti-viral treatment greatly improves
the underlying symptoms associated with Chronic Viral Hepatitis and
the progression of HBV/HCV.
- diminishes liver inflammation (Hepatitis);
- lowers elevated liver enzymes;
- lessens abdominal pain;
- minimizes liver cell damage;
- stimulates cellular regeneration in the liver;
- decreases lethargy and fatigue associated with HBV, HCV,
and anti-viral drugs;
- protects the liver against the toxic affects of drugs,
alcohol, anabolic steroids, etc.;
- helps normalize liver function;
- improves the efficacy of anti-viral drugs by improving
tolerance, reducing adverse side-effects and toxicity.